Metallothionein immunolocalization in actinic skin nonmelanoma carcinomas

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 2, 2007, Pages 165-169

  Borges Jr , Paulo C ^a   Ribeiro, Rosy I M A ^a   Cardoso, Sérgio V ^a   Berbet, Alceu L C ^a   Rocha, Ademir ^a   Espindola, Foued S ^a   Loyola, Adriano M ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

Actinic; Carcinoma; Immunohistochemistry; Metallothionein; Skin

Indexed keywords

METALLOTHIONEIN;

ARTICLE; BASAL CELL CARCINOMA; CONTROLLED STUDY; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN EPITHELIUM; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE;

AGED; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METALLOTHIONEIN; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

EID: 34249735908     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213115.27978.73     Document Type: Article

References (31)

1. Hamer DH. Metallothionein. Ann Rev Biochem. 1986;55:913-951.
2. Kägi JH, e Schäffer A. Biochemistry of metallothionein. Biochemistry. 1988;27:8509-8515.
3. Cherian MG, Jayasurya A, Boon-Huat BAY. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res. 2003;533:201-209.
4. Kondo Y, RusnakI JM, Hoyut DG, et al. Enhanced apoptosis in metallothionein-null cells. Mol Pharmacol. 1997;52:195-201.
5. Shimoda R, Achanzar WE, QU W, et al. Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci. 2003;73:294-300.
6. Gruij FR. Photocarcinogenesis: UVA vs UVB. Meth Enzymol. 2000;319:356-366.
7. Hanada K, Sawamaura D, Hashimoto I, et al. Epidermal proliferation of skin in metallothionein-null mice. J Invest Dermatol. 1998b;110:259-262.
8. Loachin E, Assimakopoulos D, Peschos D, et al. Immunohistochemical expression of MT in benign premalignant and malignant epithelium of the larynx: correlation with p53 and proliferative cell nuclear antigen. Pathol Res Pract. 1999;195:809-814.
9. Teocharis SE, Margeli AP, Klijanienko JT, et al. Metallothionein expression in human neoplasia. Histopatology. 2004;45:103-118.
10. Yamamoto M, Tsujinaka T, Shizaki H, et al. Metallothionein expression correlates with the pathological response of patients with esophageal cancer undergoing preoperative chemoradiation therapy. Oncology. 1999;56:332-337.
11. Jasani B, e Schmid KW. Significance of metallothionein overexpression in human tumors. Histopathology. 1997;31: 211-214.
12. Hanada K. Photoprotective role of MT in UV-injury MT-null mouse exhibits reduced tolerance against ultraviolet-B. J Dermatol Sci. 2000;23:51-56.
13. Kobayashi S, Hirota Y, Sayato-Suzuki J, et al. Possible role of metallothionein in the cellular defense mechanism against UVB irradiation in neonatal human skin fibroblasts. Photochem Photobiol. 1994;59:650-656.
14. Reeve VE, Nishimura N, Bosnic M, et al. Lack of metallothionein-I and -II exacerbates the immunosuppressive effect of ultraviolet B radiation and cis-urocanic acid in mice. Imunology. 2000;100:399-404.
15. Sugita K, Yamamoto O, Aschi M. Immunohistochemical analysis of MT expression in malignant melanoma in Japanese patients. Am J Dermatopathol. 2001;23:29-35.
16. Bowden GT. Prevention of non-melanoma skin cancer by targeting ultraviolet-b-light signaling. Nat Rev. 2004;4:23-35.
17. Rossen K, Haerslev T, Hou-Jensen K, et al. Metallothionein expression in basaloid proliferations overlying dermatofibromas and in basal cell carcinomas. Br J Dermatol. 1997;136:30-34.
18. Ayres M, Ayres M Jr, Ayres DM, et al. Bio Estat 3.0, Aplicações estatísticas nas áreas das ciências biológicas e médicas. Belém: Sociedade Civil Mamirauá, Brasília CNPq; 2003.
19. Cardoso SV, Barbosa HM, Candellori IM, et al. Prognostic impact of metallothionein on oral squamous cell carcinoma. Virchows Arch. 2002;441:174-178.
20. Muramatsu Y, Hasegawa Y, Fukano H, et al. Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses. Anticancer Res. 2000;20:257-264.
21. Aroni K, Theocharis S, Tsagroni E, et al. Immunoshistochemical expression of metallothionein in diferent dermal lesions. Arch Anat Cytol Path Clin Exp Pathol. 1998;46:344.
22. Mitropoulos D, Kyroudi AV, Theocharis S, et al. Prognostic significance of metallothionein in renal cell carcinoma. World J Surg Oncol. 2005;3:5.
23. Bowen AR, Hanks AN, Murphy KJ, et al. Proliferation, apoptosis, and surviving expression in keratinocytic neoplasms and hyperplasias. Am J Dermatopathol. 2004;26:177-181.
24. Stratigos AJ, Kapranos N, Petrakou E, et al. Immunophenotypic analysis of p53 gene in non-melanoma skin cancer and correlation with apoptosis and cell proliferation. JEADV. 2005;19:180-186.
25. Tilli CMLJ, Ramaekers FCS, Broers JLV, et al. Lamin expression in normal human skin, actinic keratosis, squamous cell carcinoma and basal cell carcinoma. Br J Dermatol. 2003;148:102-109.
26. Douglas-Jones AG, Schmid KW, Bier B, et al. Metallothionein expression in duct carcinoma of the breast. Human Pathol. 1995;26:217-222.
27. Rosai J. Appendix C, Staging of cancer. In: Rosai and Ackerman's Surgical Pathology. 9th ed. Philadelphia: Mosby; 2004:2801-2829.
28. Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer II:squamous cell carcinoma. Arch Dermatol. 1995;131:164.
29. Vitaliano PP, Urbach F. The relative importance of risk factors in nonmelanoma carcinoma. Arch Dermatol. 1980;116:454-463.
30. Wang W-H, Li L-F, Zhang B-X, et al. Metalothionein-null mice exhibit reduced tolerance to ultraviolet B injury in vivo. Exp Dermatol. 2004;29:57-61.
31. Ablett E, Whiteman DC, Boyle GM. Induction of metallothionein in human skin by routine exposure to sunlight: evidence for a systemic response and enhanced induction at certain body sites. J Invest Dermatol. 2003;120:318-324.